Medicare Will Test Pay Models for Radiation Oncology, Dialysis Medicare Will Test Pay Models for Radiation Oncology, Dialysis

CMS unveiled a final rule allowing Medicare to next year begin a test of bundled payment for radiation therapy. The rule also approves a kidney care model that encourages use of home-based treatments.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Related Links:

Notice of a final rule from the Centers for Medicare and Medicaid Services implementing two new mandatory Medicare payment models: the Radiation Oncology Model (RO Model) and the End-Stage Renal Disease (ESRD) Treatment Choices Model (ETC Model). The RO Model will test whether prospective episode payments to hospital outpatient departments and freestanding radiation therapy centers for radiation therapy episodes of care preserves or enhances the quality of care furnished to Medicare beneficiaries while reducing Medicare program spending. The ETC Model adjusts Medicare payments on certain dialysis and dialysis-related claim...
Source: Federal Register updates via the Rural Assistance Center - Category: Rural Health Source Type: news
Pre-publication notice of a final rule from the Centers for Medicare and Medicaid Services implementing two new mandatory Medicare payment models: the Radiation Oncology Model (RO Model) and the End-Stage Renal Disease (ESRD) Treatment Choices Model (ETC Model). The RO Model will test whether prospective episode payments to hospital outpatient departments and freestanding radiation therapy centers for radiation therapy episodes of care preserves or enhances the quality of care furnished to Medicare beneficiaries while reducing Medicare program spending. The ETC Model adjusts Medicare payments on certain dialysis and dialys...
Source: Federal Register updates via the Rural Assistance Center - Category: Rural Health Source Type: news
Conclusions: SMART provided promising oncologic outcomes at the cost of significant treatment related morbidity. Due to the significant treatment associated morbidity and favorable treatment alternatives, we have not broadly adopted SMART at our institution.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
CONCLUSIONS: The incidence of UTI was much lower than expected, suggesting that asymptomatic bacteriuria develops symptoms due to radiotherapy. Due to the low rate of UTI, no predictive factor was identified.
Source: Clinics - Category: General Medicine Source Type: research
Notice of proposed rule from the Centers for Medicare and Medicaid Services to implement two new mandatory Medicare payment models. The End-Stage Renal Disease (ESRD) Treatment Choices Model (ETC Model) is a mandatory payment model to encourage greater use of home dialysis and kidney transplants. The Radiation Oncology Model (RO Model) promotes quality and financial accountability for providers and suppliers of radiotherapy and tests whether making prospective episode payments to hospital outpatient departments and freestanding radiation therapy centers improves quality of care and reduces Medicare spending. Comments on th...
Source: Federal Register updates via the Rural Assistance Center - Category: Rural Health Source Type: news
Pre-publication notice of proposed rule from the Centers for Medicare and Medicaid Services to implement two new mandatory Medicare payment models. The End-Stage Renal Disease (ESRD) Treatment Choices Model (ETC Model) is a mandatory payment model to encourage greater use of home dialysis and kidney transplants. The Radiation Oncology Model (RO Model) promotes quality and financial accountability for providers and suppliers of radiotherapy and tests whether making prospective episode payments to hospital outpatient departments and freestanding radiation therapy centers improves quality of care and reduces Medicare spending...
Source: Federal Register updates via the Rural Assistance Center - Category: Rural Health Source Type: news
One significant change in Japan’s revised reimbursement process for new medical devices involves pricing. Applicants have been required for some time to provide pricing for their medical devices in other primary markets such as the United States, the United Kingdom, Germany, France, and Australia. Pricing has been based on list price, not market price, and the intention was to cap the reimbursement of medical devices. Given the typical differences between U.S. pricing and European pricing, the high U.S. price tended to pull the average up. (Please see the example below in Table 1; each price is converted ...
Source: MDDI - Category: Medical Devices Authors: Tags: Regulatory and Compliance Source Type: news
CONCLUSION: Application of appropriate indication for transplantectomy relies on benefit-risk balance between the interruption of immunosuppressive agents versus survival and quality of life impairment after returning to dialysis. No robust recommendation exists regarding switch of immunosuppressive drugs. Cancer predictive factors and access to a subsequent transplantation are key decisive elements. PMID: 27665407 [PubMed - as supplied by publisher]
Source: Progres en Urologie - Category: Urology & Nephrology Tags: Prog Urol Source Type: research
Conclusions Administration of intravenous cisplatin and 5-fluorouracil chemotherapy to a patient treated with continuous ambulatory peritoneal dialysis is feasible, but clearance in dialysate is nominal, thus suggesting that dose reduction is indicated for cisplatin. Systemic drug administration results in limited intraperitoneal penetration of 5-fluorouracil and inactive platinum species.
Source: Cancer Chemotherapy and Pharmacology - Category: Cancer & Oncology Source Type: research
Conclusion: there is no increased risk of doing the lymph node dissection early on.   Dr. Eggener-CON   Basics Lymph node dissections rarely done, even for large tumors, because there is no proven therapeutic or staging benefit for low risk patients.  A Mayo study revealed no data showing therapeutic benefit in high risk patients.  For clinically node negative high risk patients, there is staging value but no proven therapeutic benefit. Rate of positive nodes is associated with stage and grade; the higher the stage and grade, the more likely there will be positive nod...
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news
More News: Cancer & Oncology | Dialysis | Hematology | Medicare | Radiation Therapy | Urology & Nephrology